Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
ASP-7317 by Astellas Pharma for Dry (Atrophic) Macular Degeneration: Likelihood of Approval
ASP-7317 is under clinical development by Astellas Pharma and currently in Phase II for Dry (Atrophic) Macular Degeneration. According to...
Data Insights
ASP-7317 by Astellas Pharma for Juvenile Macular Degeneration (Stargardt Disease): Likelihood of Approval
ASP-7317 is under clinical development by Astellas Pharma and currently in Phase II for Juvenile Macular Degeneration (Stargardt Disease). According...